Heptares Therapeutics Limited - Product Pipeline Review - 2016

  • ID: 3635607
  • Company Profile
  • 45 pages
  • Global Markets Direct
1 of 4
Heptares Therapeutics Limited - Product Pipeline Review - 2016

Summary

The report ‘Heptares Therapeutics Limited - Product Pipeline Review - 2016’, provides an overview of the Heptares Therapeutics Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Heptares Therapeutics Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Heptares Therapeutics Limited
- The report provides overview of Heptares Therapeutics Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Heptares Therapeutics Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Heptares Therapeutics Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Heptares Therapeutics Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Heptares Therapeutics Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Heptares Therapeutics Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

Heptares Therapeutics Limited Snapshot

Heptares Therapeutics Limited Overview

Key Information

Key Facts

Heptares Therapeutics Limited - Research and Development Overview

Key Therapeutic Areas

Heptares Therapeutics Limited - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Out-Licensed Products

Out-Licensed Products/Combination Treatment Modalities

Heptares Therapeutics Limited - Pipeline Products Glance

Heptares Therapeutics Limited - Clinical Stage Pipeline Products

Phase I Products/Combination Treatment Modalities

Heptares Therapeutics Limited - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

Heptares Therapeutics Limited - Drug Profiles

HTL-9936

Product Description

Mechanism of Action

R&D Progress

Drug to Agonize Muscarinic M1 and M4 Receptors for Psychosis and Neurologic Diseases

Product Description

Mechanism of Action

R&D Progress

Drug to Agonize Muscarinic M4 Receptors for Psychiatric Diseases and Alzheimer's Disease

Product Description

Mechanism of Action

R&D Progress

HTL-1071

Product Description

Mechanism of Action

R&D Progress

HTL-14242

Product Description

Mechanism of Action

R&D Progress

HTL-6641

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Agonize GLP-1 Receptor for Type 2 Diabetes

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Agonize GPR39 for Type 1 and Type 2 Diabetes

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Antagonize GPCR for Inflammation

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Target GPCR for Undisclosed Indications

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize CXCR4 for Cancer and HIV

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Target GPCR for CNS Disorders

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Target mGluR2 for Schizophrenia

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Target GPCR for Pain, Cardiovascular, Metabolic and Inflammatory Disorders

Product Description

Mechanism of Action

R&D Progress

Heptares Therapeutics Limited - Pipeline Analysis

Heptares Therapeutics Limited - Pipeline Products by Target

Heptares Therapeutics Limited - Pipeline Products by Route of Administration

Heptares Therapeutics Limited - Pipeline Products by Molecule Type

Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action

Heptares Therapeutics Limited - Recent Pipeline Updates

Heptares Therapeutics Limited - Dormant Projects

Heptares Therapeutics Limited - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Heptares Therapeutics Limited, Key Information

Heptares Therapeutics Limited, Key Facts

Heptares Therapeutics Limited - Pipeline by Indication, 2016

Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016

Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016

Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016

Heptares Therapeutics Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016

Heptares Therapeutics Limited - Phase I, 2016

Heptares Therapeutics Limited - Preclinical, 2016

Heptares Therapeutics Limited - Discovery, 2016

Heptares Therapeutics Limited - Pipeline by Target, 2016

Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016

Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016

Heptares Therapeutics Limited - Pipeline Products by Mechanism of Action, 2016

Heptares Therapeutics Limited - Recent Pipeline Updates, 2016

Heptares Therapeutics Limited - Dormant Developmental Projects,2016

List of Figures

Heptares Therapeutics Limited - Pipeline by Top 10 Indication, 2016

Heptares Therapeutics Limited - Pipeline by Stage of Development, 2016

Heptares Therapeutics Limited - Monotherapy Products in Pipeline, 2016

Heptares Therapeutics Limited - Out-Licensed Products in Pipeline, 2016

Heptares Therapeutics Limited - Pipeline by Top 10 Target, 2016

Heptares Therapeutics Limited - Pipeline by Route of Administration, 2016

Heptares Therapeutics Limited - Pipeline by Molecule Type, 2016

Heptares Therapeutics Limited - Pipeline Products by Top 10 Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll